CONTEMPORARY VIEWS ON PERIPARTUM CARDIOMYOPATHY — CLINICAL PICTURE, DIAGNOSTICS, COURSE, TREATMENT (PART II)
https://doi.org/10.15829/1560-4071-2015-1-95-103
Abstract
The second part of the review of peripartum cardiomyopathy includes contemporary views of a specifics of disease onset. Detailed specifics of the disease onset is provided according to their specificity and diagnostical value. The approaches to diagnostics described beginning from physical examination to instrumental methods. Taking into account of the microparticles role on the disease onset, the importance ov their measurement is highlighted in peripartum cardiomyopathy, especially peripheral vasodilators, diuretics, ACE inhibitors, antiarrhythmic drugs, anticoagulants, pentoxyphilline, bromocryptine, cabergoline. The methods selected of artificial circulation in severe disease course and the data provided on plasmapheresis usage and implantable cardioverter-defibrillator. In general the points of delivery problems discussed.
About the Authors
N. T. Vatutin
Donetsk National Medical University n. a. M. Gorky, Donetsk, Ukraine
Ukraine
Ukraine
G. G. Taradin
Donetsk National Medical University n. a. M. Gorky, Donetsk, Ukraine
Ukraine
Ukraine
S. M. Kornienko
Donetsk National Medical University n. a. M. Gorky, Donetsk, Ukraine
Ukraine
Ukraine
A. A. Taratorina
Donetsk National Medical University n. a. M. Gorky, Donetsk, Ukraine
Ukraine
Ukraine
V. V. Ridzhok
Donetsk National Medical University n. a. M. Gorky, Donetsk, Ukraine
Ukraine
Ukraine
References
1. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from Heart Failure Association of European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur. J. Heart Failure. 2010; 12: 767-78.
2. Elkayam U. Clinical characteristics of peripartum cardiomyopathy in the United States. J. Amer. Coll. Cardiol. 2011; 58(7): 659-70.
3. Haghikia A, Podewski E, Libhaber E, et al. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy. Basic Res. Cardiol. 2013; 108(4): 366. doi: 10.1007/s00395-013-0366-9.
4. Kurbanov RD, Abdullayev TA, Mirzarahimova ST, et al. Postpartum (periportally) cardiomyopathy: some clinical features and course of the disease. Cardiology. 2012; 6: 35-9. Russian (Курбанов Р. Д., Абдуллаев Т. А., Мирзарахимова С. Т. и др. Послеродовая (перипартальная) кардиомиопатия: некоторые особенности клинической картины и течения заболевания. Кардиология. 2012; 6: 35-9).
5. Blauwet LA, Cooper LT. Diagnosis and management of peripartum cardiomyopathy. Heart. 2011; 97: 1970-1981. doi: 10.1136/heartjnl-2011-300349.
6. Johnson-Coyle L, Jensen L, Sobey A. Peripartum cardiomyopathy: review and practice guidelines. Am J. Crit. Care. 2012; 21: 89-98. doi: 10.4037/ajcc2012163.
7. Ramaraj R, Sorrell VL. Peripartum cardiomyopathy: causes, diagnosis, and treatment. Clev. Clin. J. Med. 2009; 76 (5): 289-96.
8. Wang M. Peripartum cardiomyopathy: case reports. Perman. J. 2009; 13 (4): 42-5.
9. Arora NT, Mohamad T, Mahajan N, et al. Cardiac magnetic resonance imaging in peripartum cardiomyopathy. Amer. J. Med. Sci. 2014; 347(2): 112-7.
10. Pyatt JR, Dubey G. Peripartum cardiomyopathy: current understanding, comprehensive management review and new developments. Postgrad. Med. J. 2010; 87: 34-9.
11. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy. Clinical characteristics and a comparison between early and late presentation. Circulation. 2005; 111: 2050-5.
12. Gunderson EP, Croen LA, Chiang V, et al. Epidemiology of peripartum cardiomyopathy. 2011; 118 (3): 583-91. doi: 10.1097/AOG.0b013e318229e6de.
13. Fett JD. Peripartum cardiomyopathy: a puzzle closer to solution. World J. Cardiol. 2014; 6(3): 87-99. doi: 10.4330/wjc.v6.i3.87.
14. Podymow T, August P. Antihypertensive drugs in pregnancy. Semin. Nephrol. 2011; 31: 70–85.
15. Hamad RR, Larsson A, Pernow J, et al. Assessment of left ventricular structure and function in preeclampsia by echocardiography and cardiovascular biomarkers. J. Hypertens. 2009; 27: 2257–64.
16. Lok SI, Kirkels JH, Klöpping C, et al. Peripartum cardiomyopathy: the need for a national database. Neth. Heart J. 2011; doi 10.1007/s12471-011-0083-7.
17. Ivanovich B, Tadich M, Maksimovich R, et al. Could it have been better? A patient with peripartum cardiomyopathy treated with conventional therapy. Vojnosanit Pregl. 2012; 69(6): 526–30.
18. Sliwa K, Föster O, Libhaber E, et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur. Heart J. 2006; 27: 441-6.
19. Hu CL, Li YB, Zou YG, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007; 93: 488-90.
20. Zhang F. The research into the clinical characteristics of peripartum cardiomyopathy. Heart. 2012; 98: 165-166. doi:10.1136/heartjnl-2012-302920j.17.
21. Forster O, Hilfiker-Kleiner D, Ansari AA, et al. Reversal of IFN-gamma, oxLDL and prolactin serum levels correlate with clinical improvement in patients with peripartum cardiomyopathy. Eur. J. Heart Fail. 2008; 10: 861–68.
22. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur. Heart J. 2012; 33(12): 1469-79. doi: 10.1093/eurheartj/ehr485.
23. Kim DY, Islam S, Mondal NT, et al. Biventricular thrombi associated with peripartum cardiomyopathy. J. Health Popul. Nutr. 2011; 29 (2):178-80.
24. Tibazarwa K, Lee G, Mayosi B, et al. The 12-lead ECG in peripartum cardiomyopathy. Cardiovascular J. Afr. 2012; 23: 1-8.
25. Tibazarwa K, Sliwa K. Peripartum cardiomyopathy in Africa: challenges in diagnosis, prognosis, and therapy. Progress Cardiovasc. Dis. 2010; 52: 317-25.
26. Duran N, Günes H, Duran I, et al. Predictors of prognosis in patients with peripartum cardiomyopathy. Int. J. Gynaecol. Obstet. 2008; 101: 137-40.
27. Labidi S, Hilfiker-Kleiner D, Klein G. Left bundle branch block during pregnancy as a sign of imminent peripartum cardiomyopathy. Eur. Heart J. 2011; 10.1093/eurheartj/ehq487.
28. Ibebuogu UN, Thornton JW, Reed GL. An unusual case of peripartum cardiomyopathy manifesting with multiple thrombo-embolic phenomena. Thrombosis Journal. 2007; 5: 18: 1-5. doi:10.1186/1477-9560-5-18.
29. Zeng Y, Liu YT, Yip G, et al. Intracardiac thrombi and skin necrosis in a young female patient. Arch. Med. Sci. 2013; 9 (5): 957–9.
30. Fett JD, Fristoe KL, Welsh SN. Risk of heart failure relapse in subsequent pregnancy among peripartum cardiomyopathy mothers. Int. J. Gynaecol. Obstet. 2010; 109(1): 34-6.
31. Mouquet F, Lions C, de Groote P, et al. Characterization of peripartum cardiomyopathy by cardiac magnetic resonance imaging. Europ. Radiol. 2008; 18: 2765-9.
32. Baruteau AE, Leurent G, Martins RP, et al. Peripartum cardiomyopathy in the era of cardiac magnetic resonance imaging: first results and perspectives. Int. J. Cardiol. 2010; 144(1): 143-5.
33. Webb JA, Thomsen HS, Morcos SK. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Europ. Radiol. 2005; 15: 1234-40.
34. Pearson G, Veille J, Rahimtoola S, et al. Peripartum Cardiomyopathy National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop Recommendations and Review. JAMA. 2000; 283: 1183-8.
35. Fett JD, Sannon H, Thélisma E, et al. Recovery from severe heart failure following peripartum cardiomyopathy. Int. J. Gynaecol. Obstet. 2009; 104: 125-7.
36. Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J. Cardiac. Fail. 2011; 17: 426–30.
37. Zimmerman H, Rose R, Smith R, et al. Treatment of peripartum cardiomyopathy with mechanical assist devices and cardiac transplantation. Ann. Thorac. Surg. 2010; 89: 1211-7.
38. Emmert MY, Prêtre R, Ruschitzka F, et al. Peripartum cardiomyopathy with cardiogenic shock: recovery after prolactin inhibition and mechanical support. Ann. Thorac. Surg. 2011; 91: 274-6.
39. Samonte VI, Ngalob QG, Mata GDB, et al. Clinical and echocardiographic profile and outcomes of peripartum cardiomyopathy: the Philippine General Hospital experience. Heart Asia. 2013; 5: 245-9. doi:10.1136/heartasia-2013-010356.
40. Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology. Eur Heart J. 2011; 32: 3147–97. doi: 10.1093/eurheartj/ehr218.
41. Bachelier-Walenta K, Hilfiker-Kleiner D, Sliwa K. Peripartum cardiomyopathy: 2012. Curr. Opin. Crit. Care. 2013; 19: 397-403.
42. Benezet-Mazuecos J, de la Hera J. Peripartum cardiomyopathy: a new successful setting for levosimendan. Int. J. Cardiol. 2008; 123(3): 346-7.
43. Biteker M, Duran NE, Kaya H, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin. Res. Cardiol. 2011; 100(7): 571-7.
44. Petersen KM, Jimenez-Solem E, Andersen JT, et al. b-Blocker treatment during pregnancy and adverse pregnancy outcomes: a nationwide population-based cohort study. Brit. Med. J Open. 2012; 2: e001185. doi:10.1136/bmjopen-2012-001185.
45. Mouquet F, Mostefa KM, Lamblin N, et al. Unexpected and rapid recovery of left ventricular function in patients with peripartum cardiomyopathy: impact of cardiac resynchronization therapy. Eur. J. Heart Fail. 2012; 14(5): 526-9. doi: 10.1093/eurjhf/hfs031.
46. Pillarisetti J, Kondur A, Alani A, et al. Peripartum cardiomyopathy: predictors of recovery and current stage of implantable cardioverter defibrillator use online first. J. Amer. Coll. Cardiol. 2014; doi: 10.1016/j.jacc.2014.04.014 http://www.content.onlinejacc.org/article. asp?articleID=1867290.
47. Sliwa K, Skudicky D, Candy G, et al. The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur. J. Heart Fail. 2002; 4(3): 305-9.
48. Wang TL, Hung HF, Shyu KG, et al. Successful treatment of peripartum cardiomyopathy with plasmapheresis. Acta Cardiol. Sin. 2013; 29: 471-4.
49. Elkayam U, Goland S. Bromocriptine for the treatment of peripartum cardiomyopathy. Circulation. 2010; 121: 1463-4.
50. Loyaga-Rendon RY, Pamboukian SV, Tallaj JA, et al. Outcomes of patients with peripartum cardiomyopathy who received mechanical circulatory support: data from the INTERMACS registry. Circ. Heart Failure. 2014; doi: 10.1161/circheartfailure. 113.000721.
Review
For citations:
Vatutin N.T., Taradin G.G., Kornienko S.M., Taratorina A.A., Ridzhok V.V. CONTEMPORARY VIEWS ON PERIPARTUM CARDIOMYOPATHY — CLINICAL PICTURE, DIAGNOSTICS, COURSE, TREATMENT (PART II). Russian Journal of Cardiology. 2015;(1):95-103. (In Russ.) https://doi.org/10.15829/1560-4071-2015-1-95-103
Views:
1239
Email this article 